CA3235923A1 - Methods for large scale synthesis of radionuclide complexes - Google Patents

Methods for large scale synthesis of radionuclide complexes Download PDF

Info

Publication number
CA3235923A1
CA3235923A1 CA3235923A CA3235923A CA3235923A1 CA 3235923 A1 CA3235923 A1 CA 3235923A1 CA 3235923 A CA3235923 A CA 3235923A CA 3235923 A CA3235923 A CA 3235923A CA 3235923 A1 CA3235923 A1 CA 3235923A1
Authority
CA
Canada
Prior art keywords
concentration
mother solution
range
salt
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235923A
Other languages
English (en)
French (fr)
Inventor
Donato BARBATO
Michele BO
Mattia ROSSETTO
Mattia TEDESCO
Federico VALERIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications SA
Original Assignee
Advanced Accelerator Applications SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications SA filed Critical Advanced Accelerator Applications SA
Publication of CA3235923A1 publication Critical patent/CA3235923A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3235923A 2022-02-04 2023-02-03 Methods for large scale synthesis of radionuclide complexes Pending CA3235923A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306822P 2022-02-04 2022-02-04
US63/306,822 2022-02-04
PCT/IB2023/050982 WO2023148680A1 (en) 2022-02-04 2023-02-03 Methods for large scale synthesis of radionuclide complexes

Publications (1)

Publication Number Publication Date
CA3235923A1 true CA3235923A1 (en) 2023-08-10

Family

ID=85221934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235923A Pending CA3235923A1 (en) 2022-02-04 2023-02-03 Methods for large scale synthesis of radionuclide complexes

Country Status (9)

Country Link
US (1) US20260053959A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472678A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506322A (cg-RX-API-DMAC7.html)
KR (1) KR20240146015A (cg-RX-API-DMAC7.html)
CN (1) CN118159303A (cg-RX-API-DMAC7.html)
CA (1) CA3235923A1 (cg-RX-API-DMAC7.html)
IL (1) IL313964A (cg-RX-API-DMAC7.html)
TW (1) TW202342112A (cg-RX-API-DMAC7.html)
WO (1) WO2023148680A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024317528A1 (en) * 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025210599A2 (en) 2024-04-05 2025-10-09 Novartis Ag Combination therapies with dna damage response inhibitors and [ 177lu]lu-psma-617
WO2026088112A1 (en) 2024-10-23 2026-04-30 Novartis Ag Combination therapies with ar-degrading agents and psma-targeting radioligands
WO2026099626A1 (en) 2024-11-08 2026-05-15 Novartis Ag Methods and systems for manufacturing radiopharmaceuticals
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7358451B2 (ja) * 2018-07-25 2023-10-10 アドバンスド アクセラレーター アプリケーションズ 安定な濃厚放射性核種錯体溶液
IL280314B1 (en) * 2018-07-25 2026-07-01 Advanced Accelerator Applications Sa Stable and concentrated radionuclide complex solutions
WO2020079799A1 (ja) 2018-10-18 2020-04-23 三菱電機株式会社 付加製造加工機および冷却方法
CN112969675B (zh) * 2018-10-31 2024-12-20 意大利国际先进加速器应用有限公司 用于合成放射性核素络合物的方法
MX2021015467A (es) * 2019-06-14 2022-01-24 Edinburgh Molecular Imaging Ltd Compuestos y metodos de uso.

Also Published As

Publication number Publication date
KR20240146015A (ko) 2024-10-07
WO2023148680A1 (en) 2023-08-10
US20260053959A1 (en) 2026-02-26
EP4472678A1 (en) 2024-12-11
CN118159303A (zh) 2024-06-07
IL313964A (en) 2024-08-01
TW202342112A (zh) 2023-11-01
JP2025506322A (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
US20260053959A1 (en) Methods for large scale synthesis of radionuclide complexes
KR102767449B1 (ko) 방사성핵종 착물의 합성 방법
US12605447B2 (en) Stable formulations for radionuclide complexes
JP7436512B2 (ja) 腎保護物質としてのパラアミノ馬尿酸(pah)
US20210379212A1 (en) Stable, concentrated radionuclide complex solutions
WO2020021310A1 (en) Stable, concentrated radionuclide complex solutions
WO2022051684A1 (en) Radiolabeling and formulation for scale up of 64cu-dotatate
RU2826739C2 (ru) Способы синтеза радионуклидного комплекса
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
US20090110634A1 (en) Radiolabelled nanoparticles
WO2023164769A1 (en) Radiopharmaceutical and methods
WO2026099626A1 (en) Methods and systems for manufacturing radiopharmaceuticals

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241205

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216